Khairallah Pascale, Lorenz Elizabeth C, Waterman Amy, Aggarwal Nidhi, Pai Akshta, Winkelmayer Wolfgang C, Niu Jingbo
Section of Nephrology, Baylor College of Medicine, Houston, Texas.
Section of Nephrology, Baylor College of Medicine, Houston, Texas.
Am J Kidney Dis. 2025 Mar;85(3):273-283.e1. doi: 10.1053/j.ajkd.2024.09.005. Epub 2024 Nov 7.
RATIONALE & OBJECTIVE: The management and outcomes of kidney transplant recipients have evolved over the past 3 decades. This study of US patients whose first kidney allograft failed examined long-term trends in subsequent waitlisting, retransplantation, and all-cause mortality.
Retrospective cohort study.
SETTING & PARTICIPANTS: Patients recorded in the US Renal Data System (USRDS) whose first kidney allograft failed between 1990 and 2019.
The 5-year period in which the allograft failure occurred: 1990-1994, 1995-1999, 2000-2004, 2005-2009, 2010-2014, or 2015-2019.
(1) Waitlisting for retransplantation, (2) retransplantation, and (3) all-cause mortality following first allograft failure.
Competing risk survival analyses with the approach described by Fine and Gray used for the outcomes of waitlisting and retransplantation, and Cox proportional hazards models used for the outcome of all-cause mortality.
The absolute number of patients whose allograft failed and who started dialysis increased from 3,197 in 1990 to 5,821 in 2019. Compared with 1990-1994, the rate of waitlisting for a second transplant increased with each subsequent 5-year period, peaking between 2005 and 2009 before decreasing again subsequently. The rate of retransplantation following allograft failure decreased by 9%, 14%, 18%, 7%, and 11% in the sequential 5-year eras; and the mortality rate was 25% lower in 2015-2019 (HR, 0.75 [95% CI, 0.72-0.77]) compared with 1990-1994. Women had a reduced rate of waitlisting (HR, 0.93 [95% CI, 0.91-0.95]) and lower rate of retransplantation (HR, 0.93 [95% CI, 0.91-0.95]) compared with men. Compared with White patients, African American and Hispanic patients had significantly lower rates of waitlisting, retransplantation, and mortality.
Retrospective data that lacks granular clinical information.
During the past 3 decades, among patients whose first kidney allograft failed and subsequently initiated dialysis, the rates of waitlisting for retransplantation increased while the rates of retransplantation and mortality decreased. Disparities based on race, ethnicity, and sex in waitlisting and retransplantation were observed and warrant further investigation.
PLAIN-LANGUAGE SUMMARY: Kidney allograft failure constitutes the fourth most common cause of dialysis initiation in the United States, and it accounts for 4% to 10% of yearly new dialysis starts globally. Little is known about the trends in the outcomes of patients whose kidney allograft failed. We studied US patients whose first kidney allograft failed between 1990 and 2019 to understand trends in waitlisting for retransplantation, retransplantation, and all-cause mortality after kidney allograft failure. Among patients whose first kidney allograft failed and started dialysis, rates of waitlisting increased and rates of retransplantation and mortality decreased over the past 3 decades. We found racial, ethnic, and sex-based disparities in outcomes. Compared with White patients, African American and Hispanic patients had significantly lower rates of waitlisting, retransplantation, and mortality. Women also had lower rates of waitlisting and retransplantation compared with men.
在过去30年中,肾移植受者的管理和结局发生了演变。本研究对首次肾移植失败的美国患者进行了调查,分析了后续等待名单、再次移植和全因死亡率的长期趋势。
回顾性队列研究。
美国肾脏数据系统(USRDS)中记录的1990年至2019年间首次肾移植失败的患者。
移植肾失败发生的5年时间段:1990 - 1994年、1995 - 1999年、2000 - 2004年、2005 - 2009年、2010 - 2014年或2015 - 2019年。
(1)再次移植等待名单;(2)再次移植;(3)首次移植失败后的全因死亡率。
采用Fine和Gray描述的竞争风险生存分析方法评估等待名单和再次移植的结局,采用Cox比例风险模型评估全因死亡率结局。
移植肾失败且开始透析的患者绝对数量从1990年的3197例增加到2019年的5821例。与1990 - 1994年相比,后续每个5年时间段二次移植的等待率均有所增加,在2005 - 2009年达到峰值,随后再次下降。在连续的5年时间段内,移植肾失败后的再次移植率分别下降了9%、14%、18%、7%和11%;与1990 - 1994年相比,2015 - 2019年的死亡率降低了25%(风险比,0.75 [95%置信区间,0.72 - 0.77])。与男性相比,女性的等待率(风险比,0.93 [95%置信区间,0.91 - 0.95])和再次移植率(风险比,0.93 [95%置信区间,0.91 - 0.95])较低。与白人患者相比,非裔美国人和西班牙裔患者的等待率、再次移植率和死亡率显著较低。
缺乏详细临床信息的回顾性数据。
在过去30年中,首次肾移植失败并随后开始透析的患者中,再次移植的等待率增加,而再次移植率和死亡率下降。观察到在等待名单和再次移植方面存在基于种族、民族和性别的差异,值得进一步研究。
肾移植失败是美国开始透析的第四大常见原因,占全球每年新透析开始人数的4%至10%。对于肾移植失败患者的结局趋势知之甚少。我们研究了1990年至2019年间首次肾移植失败的美国患者,以了解肾移植失败后再次移植等待名单、再次移植和全因死亡率的趋势。在首次肾移植失败并开始透析的患者中,过去30年里等待名单率上升,再次移植率和死亡率下降。我们发现了结局方面基于种族、民族和性别的差异。与白人患者相比,非裔美国人和西班牙裔患者的等待率、再次移植率和死亡率显著较低。与男性相比,女性的等待率和再次移植率也较低。